Quantcast

Latest Thalidomide Stories

2011-04-19 14:29:26

New research in the FASEB Journal details the first evidence that breakdown products of thalidomide produce the specific, toxic effects of thalidomide in embryos Thalidomide may have been withdrawn in the early 1960s for use by pregnant women, but its dramatic effects remain memorable half a century later. Now, researchers have taken a major step toward understanding exactly how thalidomide causes the birth defects. This is important as thalidomide is still used to treat diseases like...

2011-04-03 21:51:37

Well-known drug provides new hope for difficult to treat liver cancer patients Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma (HCC), according to data presented at the International Liver CongressTM 2011. A new study found thalidomide gave HCC patients who'd undergone grossly curative resection surgical removal of the cancerous part of the liver double the two-year disease free survival rate (65%) compared to placebo (33%). However, the...

2010-12-13 21:29:58

UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age. The team found that extremely low doses of the drug lenalidomide can stimulate the body's immune-cell protein factories, which decrease production during aging, and rebalance the levels of several key cytokines "“ immune proteins that either attack viruses and bacteria or cause inflammation that...

2010-12-07 08:12:00

In the news release, Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study, issued 07-Dec-2010 by Onyx Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the sixth paragraph, first sentence, should read "In a subset analysis of patients who were refractory to bortezomib in their last line of therapy (n=128), carfilzomib achieved an ORR of 19 percent and CBR of 31 percent" rather than " In a subset analysis of patients who were...

2010-12-07 06:30:00

EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved an overall response rate (ORR) (partial response or greater) of 24.1 percent and a median duration of response (DOR) of 8.3 months in patients who entered the study after...

2010-12-06 10:22:00

BURLINGTON, Mass., Dec. 6, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of Celgene's Revlimid in the first-line setting and the launch of several premium-priced emerging therapies will drive robust 7.2 percent annual growth through 2019 in the multiple myeloma drug market. The Pharmacor 2010 findings from the topic entitled Multiple Myeloma which will publish later...

2010-11-30 07:00:00

WHITE PLAINS, N.Y. and CHAPPAQUA, N.Y., Nov. 30, 2010 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and BioTheryX, Inc. announced today that they have entered into a partnership to accelerate the development of new therapies for hematological malignancies with an initial focus on acute myelogenous leukemia (AML). The partnership marks the first time that LLS has provided funds through the acquisition of equity. LLS has provided $4.5 million in financing through its Therapy...

2010-09-23 08:00:00

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of multiple myeloma, more surveyed European hematologist-oncologists consider the combination of immunomodulatory agents and proteasome inhibitors promising with respect to efficacy than is the case for any other drug regimen combinations. In light of these findings, the emerging regimen of Onyx...

2010-07-26 06:00:00

EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. In an independent review of the data, carfilzomib achieved an overall response rate (partial response or greater) of 24 percent and a median duration of response of 7.4 months in...

2010-06-05 16:30:00

EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma. In 53 evaluable patients who had not been previously...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.